Hot Deals:
amol minechem 601.00 (0.17 %) anglo french drugs 930.00 (3.33 %) anugraha valve 280.00 (1.82 %) apl metals 40.00 (-2.44 %) apollo fashion 107.00 (1.90 %) archit nuwood 500.00 arkfin investments 50.00 arohan 202.00 (1.00 %) assam carbon 265.00 (1.92 %) avalokiteshvar 242.00 (0.83 %) axles india 610.00 (1.67 %) balmer lawrie 202.00 (1.00 %) bharat hotels 345.00 (1.47 %) bima mandi 235.00 (-2.08 %) bira 555.00 (-0.89 %) boat 1,380.00 (-1.43 %) c & s electric 840.00 (-1.18 %) cable corporation 13.00 (-0.76 %) capgemini 11,900.00 (0.85 %) care health 186.00 (-1.59 %) carrier aircon 545.00 (-0.91 %) cial 326.00 (0.31 %) csk 170.00 (-1.16 %) dalmia refract 260.00 (1.96 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 440.00 (3.53 %) electronica plastic 2,100.00 (-0.99 %) elgi ultra 400.00 elofic 2,100.00 (2.44 %) esl steel 46.00 (1.10 %) fincare business 86.00 (3.61 %) fincare sfbl 205.00 (1.49 %) fino paytech 133.00 (-1.48 %) flipkart india 231,001.00 (0.00 %) frick india 15,600.00 (-0.95 %) gkn driveline 1,325.00 (-0.38 %) godavari bio 71.00 (1.43 %) goodluck defence 235.00 (2.17 %) group pharma 300.00 gynofem healthcare 63.00 (-3.08 %) hazira cargo terminals limited 205.00 (1.49 %) hdb financial 1,120.00 (-0.88 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,300.00 (-1.74 %) hella india 910.00 (1.11 %) hero fincorp 1,990.00 (-0.50 %) hexaware 720.00 (-2.70 %) hicks 1,450.00 (2.11 %) hira ferro 180.00 (2.86 %) honeywell electrical 6,200.00 (1.64 %) ikf finance 312.00 (0.65 %) incred financial 10.00 (1.01 %) incred holdings 165.00 (-1.79 %) india carbon 1,135.00 (-1.30 %) india exposition 121.00 (0.83 %) indian potash 3,250.00 (1.56 %) indian seamless 175.00 (2.94 %) indo alusys 25.75 (-0.96 %) indofil 1,030.00 (0.49 %) infinite computer 405.00 (1.25 %) inkel 29.00 (-3.33 %) jana small finance bank 75.00 kel 610.00 (-2.40 %) kial 126.00 (-1.56 %) klm axiva 15.75 (1.61 %) kurlon limited 1,255.00 (0.40 %) lava 49.00 (-2.00 %) mahindra rural mrhfl 100.00 manipal housing 74.00 (2.07 %) manjushree technopack 3,050.00 (0.66 %) martin & harris 975.00 (-1.52 %) matrix gas 950.00 (-1.04 %) merino 3,350.00 (1.52 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 410.00 (-2.38 %) mobikwik 595.00 (-0.34 %) mohan meakin 2,150.00 (2.38 %) mohfl 13.60 (-0.73 %) msei 1.15 (-0.86 %) msil 36.00 (2.86 %) nayara energy 595.00 (-0.83 %) nayara energy ncd 315.00 (3.28 %) ncdex 220.00 (-0.90 %) ncl buildtek 310.00 (3.33 %) ncl holdings 92.00 (1.10 %) northern arc 400.00 nsdl 825.00 (1.85 %) nse 5,700.00 (1.79 %) orbis financial 340.00 (0.29 %) oswal minerals 60.10 (-1.48 %) otis 3,700.00 (-0.67 %) oyo 43.50 (-1.14 %) panasonic appliances 262.00 (0.77 %) paymate india 520.00 (-0.95 %) pharmeasy 8.50 (-2.30 %) pharmed limited 480.00 (2.13 %) philips domestic 720.00 (-1.37 %) philips india 910.00 (-1.09 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 255.00 (-1.92 %) rapido 16,650.00 (0.03 %) rasoi 31,500.00 (0.32 %) reliance gic 505.00 (1.00 %) resins plastics 475.00 (3.26 %) ring plus aqua 530.00 (0.95 %) rrl 1,275.00 (2.00 %) rrp s4e innovation 345.00 (-1.43 %) sab miller 490.00 (2.94 %) sbi amc 2,150.00 (0.94 %) sbi general insurance 620.00 (3.33 %) scottish assam 480.00 (2.13 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,330.00 (-0.75 %) smile microfinance 55.00 (1.85 %) sterlite power 748.00 (-0.27 %) studds 915.00 (-1.08 %) svsml 315.00 (2.94 %) swiggy 355.00 (1.43 %) t stanes 810.00 (1.25 %) tata capital 1,040.00 (-0.95 %) teesta agro 77.00 (-6.21 %) trl krosaki 1,300.00 (1.96 %) urban tots 92.00 (2.22 %) utkarsh coreinvest 310.00 (3.33 %) vadilal dairy 10.00 vikram solar 285.00 (-1.72 %) vivriti capital 1,150.00 (-0.86 %) waree energies 2,150.00 (-0.46 %)
×

Anglo French Annual Reports, Balance Sheet and Financials

Anglo French Drugs And Industries Limited (Anglo French Drugs) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
Anglo French Drugs And Industries Limited

 

Anglo French Drugs and Industries Limited Balance Sheet (Rs in Lakhs)

Particulars

31-03-2024

31-03-2023

ASSETS

 

 

Non-current assets

 

 

Property, plant and equipment

1,541

1,311

Right of Use of Assets

216

484

Intangible Assets

16

20

Investments

51

41

Other Financial Assets

684

770

Current assets

 

 

Inventories

1,197

903

Trade Receivables

4,181

5,914

Cash and cash equivalents

9

284

Bank balances other than cash equivalents

240

585

Investments

12,469

16,151

Other financial assets

1,268

635

Other current assets

88

187

TOTAL ASSETS

21,960

27,285

EQUITY AND LIABILITIES

 

 

Equity

 

 

Equity Share capital

123

129

Other Equity

16,967

20,755

Total Equity

17,090

20,884

LIABILITIES

 

 

Non Current Liabilities

 

 

Borrowings

714

1,696

Other financial liabilities

71

123

Deferred tax liabilities (net)

96

84

Other Non Current Liabilities

266

570

Employee Benefit Obligations

156

121

Current liabilities

 

 

Borrowings

188

910

Micro and Small Enterprises

254

110

Other than Micro and Small Enterprises

1,816

1,807

Other current financial liabilities

1,127

940

Short-term Provisions

48

49

Current Tax Liabilities/Asset

134

-9

TOTAL EQUITY AND LIABILITIES

21,960

27,285

 

 

Anglo French Drugs and Industries Limited Profit & Loss Statement (Rs in Lakhs)

 

Particulars

31-03-2024

31-03-2023

Income

 

 

Revenue from operations

9,520

10,251

Other income

464

759

Total Revenue

9,984

11,010

Expenses

 

 

Cost Of Materials Consumed

3,032

2,875

Purchases of Stock-in-Trade

3,974

3,896

Changes in inventories of Finished Goods, Work in Progress and Stock in Trade

-184

956

Employee benefits expense

1,945

2,329

Finance costs

185

307

Depreciation and amortization expense

315

334

Other expenses

1,946

4,332

Total Expenses

11,213

15,029

Profit/(loss) before exceptional items and tax

-1,229

-4,019

Exceptional items

-

29,127

Profit before tax

-1,229

25,108

Current tax

-

5,950

Deferred tax

12

64

Tax effect on items reclassified

-7

-

Profit/(Loss) for the year

-1,234

19,094

Other Comprehensive Income

 

 

Items that will not be reclassified to Profit or Loss

-8

5

Remeasurement of post-employment benefit

-27

-67

Total Other Comprehensive Income / (Loss)

-28

-62

Total Comprehensive Income for the year

-1,262

19,031

Earnings per share (Face value Rs 10/-basic and Diluted)

-99

1,478

 

 

Anglo French Drugs and Industries Limited Consolidated Cash Flow Statement (Rs in Lakhs)

 

Particulars

31-03-2024

31-03-2023

Cash flow from operating activities

 

 

Profit before tax

-1,229

25,108

Adjustments for:

 

 

Depreciation and amortization

315

334

Interest expense

185

307

Interest income

-240

-344

Provisions Written Back

-

-24

(Gain)/loss on Investment

-126

-

Dividend income

-28

-45

Operating profit before working capital changes

-1,125

25,338

Adjustments for changes in:

 

 

(Increase)/Decrease Trade Receivables

1,733

-2,534

(Increase)/Decrease Inventories

-294

2,374

(Increase)/Decrease in Financial Assets (Current)

-633

-348

(Increase)/Decrease in Financial Assets (Non-current)

86

-

(Increase)/Decrease in Other assets (Current)

101

135

(Increase)/Decrease in Other assets (Non-current)

-

-

Increase/(Decrease) in Trade payables

152

-313

Increase/(Decrease) in Financial liabilities (Current)

187

-177

Increase/(Decrease) in Financial liabilities (Non-current)

-52

-

Increase/(Decrease) in Other liabilities (Current)

-

35

Increase/(Decrease) in Other liabilities (Non-Current)

-303

-

Cash generated from operations

 

 

Income tax refund received / (paid) (net)

143

-6,040

Net cash flow from operating activities before exceptional items

-6

18,471

Exceptional items

-

-

Net cash flow from operating activities

-6

18,471

Cash flow from investing activities

 

 

Payments for acquisition of assets

-408

-282

Proceeds from disposal of Property, Plant and Equipment

133

-

Investments (Current and Non-current)

3,798

-16,679

Investment in bank deposits

345

-468

Dividend Received

28

45

Interest received

240

344

Net cash flow used in investing activities

4,136

-17,040

Cash flow from financing activities

 

 

Changes in long term borrowings

-982

-297

Changes in short term borrowings

-722

-566

Interest paid - Net

-185

-307

Buyback of Shares including Tax thereon

-2,259

-

Dividend paid and tax thereon

-258

-

Net cash flow from financing activities

-4,406

-1,170

Net cash inflow / (outflow)

-276

261

Opening cash and cash equivalents

284

23

Closing cash and cash equivalents

9

284

Here is the analysis of cash flow for year March 2024 and 2023:

Profit before tax: In the financial year ending March 31st, 2024, the company reported a loss before tax amounting to -1,229 units (currency unspecified), a significant decrease from the profit before tax of 25,108 units reported in the previous year, March 31st, 2023. This decrease indicates a downturn in profitability year-over-year.

Adjustments for depreciation and amortization: Depreciation and amortization expenses totaled 315 units in 2024, slightly lower than the 334 units recorded in 2023. These adjustments reflect the non-cash expenses related to the wear and tear of assets over time.

Interest expense and income: The company paid 185 units in interest expenses in 2024, compared to 307 units in 2023, indicating a decrease in interest costs. Conversely, interest income showed a reduction from -344 units in 2023 to -240 units in 2024, potentially due to lower interest earnings on investments.

Provisions written back and gains/losses on investments: There were no provisions written back in either year. However, the company recorded a loss of -126 units on investments in 2024, whereas no such loss was reported in 2023. This reflects a negative impact on earnings from investments.

Dividend income: Dividend income decreased from -45 units in 2023 to -28 units in 2024, indicating lower dividend earnings for the company.

Operating profit before working capital changes: The operating profit before adjustments for changes in working capital was -1,125 units in 2024, significantly lower than the 25,338 units reported in 2023. This substantial decrease reflects the overall decline in operating profitability.

Changes in working capital: There were several adjustments in working capital components:

Trade receivables increased by 1,733 units in 2024, compared to a decrease of -2,534 units in 2023.

Inventories decreased by -294 units in 2024, following an increase of 2,374 units in 2023.

Current financial assets decreased by -633 units in 2024, compared to a decrease of -348 units in 2023.

Non-current financial assets increased by 86 units in 2024, whereas no change was reported in 2023.

Other current assets increased by 101 units in 2024, compared to an increase of 135 units in 2023.

Trade payables increased by 152 units in 2024, following a decrease of -313 units in 2023.

Current financial liabilities increased by 187 units in 2024, whereas they decreased by -177 units in 2023.

Non-current financial liabilities decreased by -52 units in 2024, with no change reported in 2023.

Other current liabilities did not change in 2024, while they increased by 35 units in 2023.

Other non-current liabilities decreased by -303 units in 2024, with no change reported in 2023.

Cash generated from operations: The net cash flow from operating activities before exceptional items was -6 units in 2024, compared to 18,471 units in 2023. This significant decrease indicates a substantial decline in cash generated from core operational activities.

Cash flow from investing activities: The company invested 4,136 units in various activities in 2024, primarily driven by payments for acquisition of assets and investments, compared to a cash outflow of -17,040 units in 2023. This shift reflects a strategic redirection of investment priorities.

Cash flow from financing activities: Financing activities in 2024 resulted in a net cash outflow of -4,406 units, compared to -1,170 units in 2023. This increase in outflow was due to changes in long-term and short-term borrowings, buyback of shares, and dividend payments.

Net cash inflow/outflow: Overall, the company experienced a net cash outflow of -276 units in 2024, contrasting with a net inflow of 261 units in 2023. This change underscores the company's cash management challenges and strategic financial decisions over the year.

Opening and closing cash and cash equivalents: The period started with 284 units of cash and cash equivalents in 2024, increased to 284 units by the end of the period. In contrast, 2024 saw a decrease from 23 units to 9 units.

Financial Ratios of Anglo French Drugs and Industries Limited

Ratio

2024

2023

Current Ratio

5.45

6.48

Debt Equity Ratio

0.05

0.12

Debt Service Coverage Ratio

-5.14

104.97

Return on Equity Ratio

-0.02

0.42

Inventory Turnover (no of days)

0.15

0.31

Debtors Turnover Ratio

0.53

0.45

Payables Turnover Ratio

0.28

0.31

Net Capital Turnover

0.6

0.49

Net Profit Margin (%)

-0.13

1.73

Here is the summary of financial and operational metrics for Anglo French Drugs And Industries Limited for year 2024 & 2023:

Current Ratio:

2024: 5.45

2023: 6.48

Insight: The current ratio measures the company's ability to meet its short-term obligations with its short-term assets. A decrease from 6.48 in 2023 to 5.45 in 2024 indicates a slight reduction in liquidity. However, both ratios are comfortably above 1, indicating a strong ability to cover short-term liabilities.

Debt Equity Ratio:

2024: 0.05

2023: 0.12

Insight: The debt equity ratio measures the proportion of debt and equity financing used by the company. A decrease from 0.12 in 2023 to 0.05 in 2024 suggests a reduction in reliance on debt financing relative to equity, indicating potentially improved financial stability.

Debt Service Coverage Ratio:

2024: (-5.14)

2023: 104.97

Insight: The debt service coverage ratio assesses the company's ability to cover its debt obligations with its operating income. A negative ratio in 2024 (-5.14) indicates that the company's operating income was insufficient to cover its debt servicing obligations during that period. This is a significant decline from a very strong coverage ratio of 104.97 in 2023, suggesting increased financial strain.

Return on Equity Ratio:

2024: (-0.02)

2023: 0.42

Insight: The return on equity (ROE) ratio measures how effectively the company generates profits from shareholders' equity. A negative ROE in 2024 (-0.02) indicates a loss during the period, contrasting with a positive ROE of 0.42 in 2023. This reflects a decrease in profitability and potential financial challenges.

Inventory Turnover (no of days):

2024: 0.15

2023: 0.31

Insight: The inventory turnover ratio measures how efficiently the company manages its inventory. A decrease from 0.31 days in 2023 to 0.15 days in 2024 suggests that the company is holding onto inventory for fewer days, indicating potentially improved inventory management efficiency.

Debtors Turnover Ratio:

2024: 0.53

2023: 0.45

Insight: The debtors turnover ratio measures how efficiently the company collects payments from its customers. An increase from 0.45 in 2023 to 0.53 in 2024 indicates improved efficiency in collecting receivables.

Payables Turnover Ratio:

2024: 0.28

2023: 0.31

Insight: The payables turnover ratio measures how quickly the company pays its suppliers. A slight decrease from 0.31 in 2023 to 0.28 in 2024 suggests a slight increase in the time taken to pay suppliers, which could be indicative of changing payment terms or business conditions.

Net Capital Turnover:

2024: 0.60

2023: 0.49

Insight: The net capital turnover ratio measures how effectively the company utilizes its capital to generate revenue. An increase from 0.49 in 2023 to 0.60 in 2024 indicates improved efficiency in capital utilization and revenue generation.

Net Profit Margin (%):

2024: −0.13-0.13%−0.13

2023: 1.73%

Insight: The net profit margin measures the percentage of revenue that translates into profit after all expenses. A negative net profit margin in 2024 (-0.13%) indicates a loss, contrasting with a positive net profit margin of 1.73% in 2023. This reflects a decline in profitability and financial performance.

Dividend History

Particulars

2024

2023

Dividend Per Share (Rs)

1.5

-

Retained Earnings(In lakhs)

16,088

19,868

Anglo French Drugs And Industries Limited Recent Financial Performance:

Dividend per Share: The specific dividend per share figure for March 2024 is Rs. 1.50 and 2023 is not provided; Dividend per share represents the portion of a company's earnings that is distributed to shareholders in the form of dividends. A higher dividend per share may indicate that the company is sharing more of its profits with shareholders.

Retained Earnings: Retained earnings for 2024 amounted to Rs. 16,088 Lakhs, while in 2023, they were Rs. 19,868 Lakhs. Retained earnings represent the portion of a company's profits that is reinvested in the business rather than distributed as dividends. An increase in retained earnings suggests that the company has retained more of its profits for reinvestment or future growth.

To provide a more comprehensive analysis, it would be necessary to consider additional financial metrics such as revenue, net profit, assets, liabilities, and cash flows. Additionally, an analysis of trends over multiple years and a comparison to industry benchmarks and competitors would help in assessing the company's financial health and performance.

 

Annual Report

Anglo French Drugs Annual Report 2023-24

Download

Anglo French Drugs Annual Report 2022-23

Download

Anglo French Drugs Annual Report 2020-21

Download

Anglo French Drugs And Industries Annual Report 2021-22

Download

Corporate Actions

2019-20

Download

2019-20

Download

2019-20

Download

Anglo French Drugs Buyback Offer 2023-24

Download

Anglo French Drugs Buyback Offer letter 2023-24

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha

News Alert